Medclair merges subsidiary and updates patent valuation – expected to generate a positive one-off effect of approximately MSEK 30
Medclair merges subsidiary and updates patent valuation – expected to generate a positive one-off effect of approximately MSEK 30
Medclair AB has, as part of the company's ongoing efficiency efforts, decided to merge its wholly-owned subsidiary Medclair Sweden AB with the parent company.
The purpose of the merger is to create a more transparent and straightforward corporate structure for shareholders, investors, and other stakeholders. A simplified corporate structure facilitates both external and internal reporting, while reducing the administrative burden and costs associated with maintaining two separate companies within the same business segment. The consolidated structure is also assessed to enhance transparency towards Medclair's shareholders.
In parallel, the company's management has conducted a review of the valuation of Medclair's patent portfolio. Historical accounting has primarily been based on incurred development and patent costs rather than an assessment of the patents' actual market value.
An initial valuation, based primarily on the company's existing customer base and the products currently commercially available, indicates a market value of approximately MSEK 34. The valuation was conducted by an independent external party and subsequently reviewed by the company's auditors. The completed valuation does not include the patents and intellectual property rights relating to the new technology platform previously presented by the company. The current valuation thus solely reflects the value of Medclair's established product portfolio and should be considered an initial valuation of the patent portfolio.
The company's ambition is to continuously review the patent valuation as the customer base grows, existing products gain increased market penetration, and new products are launched, to ensure that the valuation better reflects the commercial value built up over time.
In connection with the merger, the patent portfolio will be transferred to the parent company at the currently assessed market value of approximately MSEK 34. The transaction is expected to generate an accounting, non-cash profit of approximately MSEK 30, which is expected to become visible in the reporting during the third quarter of 2026.
The merger does not affect Medclair's operational activities or the company's customers, but is part of the work to create a more efficient and transparent corporate structure. Further information regarding the implementation of the merger and its accounting effects will be provided in connection with the company's upcoming financial reporting.
Jonas Lundh
CEO
Medclair AB